NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited MESOMSB)), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce that it has appointed Dr. Philip R. Krause, a member of the Board of Directors, to a formal strategic advisory role. Dr. Krause was formerly Deputy…Read More
Mesoblast Director Philip R Krause MD Appointed to Strategic Advisory Role Mesoblast NASDAQMESO
